Updates on DTC advertising and DTP…
Updates on DTC advertising and DTP programs, as well as [...]
After a series of ownership…
After a series of ownership changes, Andexxa is slated to [...]
The Elevidys-related manufacturing…
The Elevidys-related manufacturing shortfalls were described in one of two [...]
Sixteen months after luring former…
Sixteen months after luring former Roche dealmaker James Sabry, M.D., [...]
As the FDA steadily churns out a…
As the FDA steadily churns out a stream of untitled [...]
Amgen, Boehringer Ingelheim,…
Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Gilead Sciences, GSK, Merck [...]
Venture capital firm Aditum Bio is…
Venture capital firm Aditum Bio is going all-out for a [...]
Merck & Co. is turning down…
Merck & Co. is turning down its option to license [...]
Altimmune has shared an update on…
Altimmune has shared an update on the metabolic dysfunction-associated steatohepatitis [...]
Boehringer Ingelheim has turned…
Boehringer Ingelheim has turned down its chance to license Nxera [...]